**Study Protocol Assessment Form**

|  |
| --- |
| **STUDY PROTOCOL INFORMATION** |
| **MMMC-RERC Code:** |  |
| **Study Protocol Title:** |  |
| **Principal Investigator:** | <Title, Given Name, Surname> |
| **Study Protocol Submission Date:** | <dd/mm/yyyy> |

|  |  |
| --- | --- |
| **Institution:**  | **Contact No/Nos.**  |
| **Total No. of Participants:** |  | **No. of Study site:**  |  |
| **Funding Agency:** |  | **Contact No.** |
| **Duration of the Study:** |  | **Status:** | **⬜ Initial⬜ Re-submitted** |
| **Type of the Study**  | **⬜ Intervention ⬜ Epidemiology ⬜ Observation** **⬜ Document based ⬜ Individual based ⬜ Genetic****⬜ Social Survey ⬜ Others, specify\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_** |
| **Description of the Study in brief: Mark whatever applied to the study.** **⬜ Randomized ⬜ Stratified Randomized ⬜ Open-labeled****⬜ Double blinded ⬜ Placebo controlled ⬜ Treatment controlled** **⬜ Cross-over ⬜ Parallel ⬜ Interim Analysis****⬜ Use of Tissue**  **samples ⬜ Use of Blood samples ⬜Use of genetic materials****⬜ Multicenter study ⬜ Screening ⬜ Descriptive** |

**INSTRUCTIONS**

|  |  |
| --- | --- |
| To the Principal Investigator: | Please indicate in the space provided below whether or not the specified assessment point is addressed by your study protocol. To facilitate the evaluation of the assessment point, indicate the page and paragraph where this information can be found. |
| To the Primary Reviewer: | Please evaluate how the assessment points outlined below have been appropriately addressed by the study protocol, as applicable, by confirming the submitted information and putting your comments in the space provided under “REVIEWER COMMENTS.” Finalize your review by indicating your conclusions under “RECOMMENDED ACTION” and signing in space provided for the primary reviewer.  |
|  |  |  |
| **ASSESSMENT POINTS** | Indicate if the study protocol contains the specified assessment point | Page and paragraph where it is found (*To be filled out by the PI)* | **REVIEWER COMMENTS** |
| 1. **SCIENTIFIC DESIGN**
 | **YES** | **N/A** |  |  |
| * 1. **Objectives**

*Review of viability of expected output* |  |  |  |  |
| * 1. **Literature review**

*Review of results of previous animal/human studies showing known risks and benefits of intervention, including known adverse drug effects, in case of drug trials* |  |  |  |  |
| * 1. **Research design**

*Review of appropriateness of design in view of objectives* |  |  |  |  |
| * 1. **Sampling design**

*Review of appropriateness of sampling methods and techniques* |  |  |  |  |
| * 1. **Sample size**

*Review of justification of sample size* |  |  |  |  |
| * 1. **Statistical analysis plan (SAP)**

*Review of appropriateness of statistical methods to be used and how participant data will be summarized* |  |  |  |  |
| * 1. **Data analysis plan**

*Review of appropriateness of statistical and non-statistical methods of data analysis*  |  |  |  |  |
| * 1. **Inclusion criteria**

*Review of precision of criteria both for scientific merit and safety concerns; and of equitable selection* |  |  |  |  |
| * 1. **Exclusion criteria**

*Review of criteria precision both for scientific merit and safety concerns; and of justified exclusion* |  |  |  |  |
| * 1. **Withdrawal criteria**

*Review of criteria precision both for scientific merit and safety concerns* |  |  |  |  |
| 1. **CONDUCT OF STUDY**
 |  |  |  |  |
| * 1. **Specimen handling**

*Review of specimen storage, access, disposal, and terms of use* |  |  |  |  |
| * 1. **PI qualifications**

*Review of CV and relevant certifications to ascertain capability to manage study related risks* |  |  |  |  |
| * 1. **Suitability of site**

*Review of adequacy of qualified staff and infrastructures, including applicability of MMMC-RERC F-3-G and MMMC-RERC F-3-H.* |  |  |  |  |
| * 1. **Duration**

*Review of length/extent of human participant involvement in the study* |  |  |  |  |
| 1. **ETHICAL CONSIDERATIONS**
 |  |  |  |  |
| * 1. **Conflict of interest**

*Review of management of conflict arising from financial, familial, or proprietary considerations of the PI, sponsor, or the study site* |  |  |  |  |
| * 1. **Privacy and confidentiality**

*Review of measures or guarantees to protect privacy and confidentiality of participant information as indicated by data collection methods including data protection plans*  |  |  |  |  |
| * 1. **Informed consent process**

*Review of application of the principle of respect for persons, who may solicit consent, how and when it will be done; who may give consent especially in case of special populations like minors and those who are not legally competent to give consent, or indigenous people which require additional clearances* |  |  |  |  |
| * 1. **Vulnerability**

*Review of involvement of vulnerable study populations and impact on informed consent (see 3.3). Vulnerable groups include children, the elderly, ethnic and racial minority groups, the homeless, prisoners, people with incurable disease, people who are politically powerless or junior members of a hierarchical group. Vulnerability must always be assessed in the context of the protocol and the participants.* |  |  |  |  |
| * 1. **Recruitment**

*Review of manner of recruitment including appropriateness of identified recruiting parties* |  |  |  |  |
| * 1. **Assent**

*Review of feasibility of obtaining assent vis à vis incompetence to consent; Review of applicability of the assent age brackets in children:**0-under 7: No assent**7-under 12: Verbal Assent**12-under15: Simplified Assent Form**15-under18:Co-sign informed consent form with parents* |  |  |  |  |
| * 1. **Risks**

*Review of level of risk and measures to mitigate these risks (including physical ,psychological, social, economic), including plans for adverse event management; Review of justification for allowable use of placebo as detailed in the Declaration of Helsinki (as applicable)* |  |  |  |  |
| * 1. **Benefits**

*Review of potential direct benefit to participants; the potential to yield generalizable knowledge about the participants’ condition/problem; non-material compensation to participant (health education or other creative benefits), where no clear, direct benefit from the project will be received by the participant* |  |  |  |  |
| * 1. **Incentives or compensation**

*Review of amount and method of compensations, financial incentives, or reimbursement of study-related expenses* |  |  |  |  |
| * 1. **Community considerations**

*Review of impact of the research on the community where the research occurs and/or to whom findings can**be linked; including issues like stigma or draining of local capacity; sensitivity to cultural traditions, and involvement of the community in decisions about the conduct of study* |  |  |  |  |
| * 1. **Collaborative study terms of reference**

*Review of terms of collaborative study especially in case of multi-country/multi-institutional studies, including intellectual property rights, publication rights, information and responsibility sharing, transparency, and capacity building* |  |  |  |  |
| * 1. **Other issues**

*Review of issues not subsumed in the issues covered by items 3.1 to 3.11* |  |  |  |  |
| Principal Investigator’s Signature: |
| RECOMMENDED ACTION:* APPROVED
* MAJOR MODIFICATIONS
* MINOR MODIFICATIONS
* REQUEST FOR INFORMATION
* DISAPPROVED
 |
| JUSTIFICATION FOR RECOMMENDED ACTION*(To be filled out by MMMC-RERC)* |
| **PRIMARY REVIEWER** | Signature  | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| Date: <dd/mm/yyyy> | Name | <Title, Given Name, Surname> \_\_\_\_\_  |
| **RERC- ADMINISTRATIVE STAFF** | Signature | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_  |
| Date: <dd/mm/yyyy> | Name | <Title, Given Name, Surname>\_\_\_\_\_\_\_\_ |